J&J Says 250,000 Ebola Vaccine Doses to Be Ready by May
This article is for subscribers only.
Johnson & Johnson plans to have 250,000 doses of experimental Ebola vaccine ready for clinical trials in May, potentially putting it ahead of GlaxoSmithKline Plc in the race to combat the virus that has killed thousands in West Africa.
The vaccine combines a shot from J&J’s Janssen unit in the Netherlands with one developed by Danish biotechnology company Bavarian Nordic A/S, the U.S.-based company said in a statement today. The course will be tested in healthy volunteers in January, and the companies aim to produce 1 million doses in 2015, Paul Stoffels, J&J’s chief scientific officer, told reporters on a call today.